Tridek-One is a technology company.
Tridek-One has raised $16.0M across 1 funding round.
Tridek-One has raised $16.0M in total across 1 funding round.
Tridek-One Therapeutics is a private biotechnology company founded in 2018 as a spin-off from INSERM in Paris, France, specializing in first-in-class CD31 checkpoint agonists for treating autoimmune and inflammatory diseases[1][2][3][4]. The company develops therapeutic bispecific antibodies that target the CD31 ITIM receptor to modulate ITAM receptor activation, restoring immune balance in both adaptive and innate immune responses without causing broad immunosuppression[1][2][3]. It serves patients with high unmet needs in immunology, backed by €19.39M in total funding, including a €16M round in 2022 from investors like Pureos Bioventures, Bpifrance, Bioqube Ventures, Advent France Biotechnology, and Advent Life Sciences[1][2][3]. With a small team (<25 employees) and operations extending to Lausanne, Switzerland, Tridek-One is advancing discovery programs and holds one patent related to cell biology and immune clusters[1][2][5].
Tridek-One emerged from groundbreaking INSERM research in Paris on the CD31 receptor's role in immune modulation, led by scientific founders who identified its potential as an ITIM receptor to inhibit overactive immune responses[1][3][4]. Founded in 2018, the company quickly secured €3M in seed funding in 2019 from Advent France Biotechnology and Advent Life Sciences, validating early proof-of-concept for CD31 agonists[3]. A pivotal €16M Series Seed VC-II round closed in September 2022, led by Pureos Bioventures with new and existing investors, fueling pipeline development amid rising demand for novel immunomodulators[1][2][3]. Headquartered at 4 Rue Thénard in Paris with a Swiss branch in Lausanne, it reflects a European focus driven by an experienced management team and advisors[1][4][5].
Tridek-One rides the wave of next-generation immunotherapy, shifting from broad immunosuppressants to precise checkpoint agonists amid a surge in autoimmune disease prevalence (e.g., rheumatoid arthritis, lupus) driven by aging populations and environmental factors[1][2][3]. Timing aligns with post-2020 biotech funding boom in Europe, where ITIM receptor targeting fills gaps left by PD-1/PD-L1 inhibitors, offering non-oncology immune reset[3][4]. Market tailwinds include €16M+ raises signaling investor confidence in antibody engineering, while the company's INSERM spin-off status amplifies France-Switzerland biotech hubs' influence on global pipelines[1][2][5]. It contributes to the ecosystem by validating CD31 as a versatile target, potentially inspiring agonist therapies beyond autoimmunity.
Tridek-One is poised to advance CD31 agonists into clinical stages, leveraging its €19M war chest for candidate nomination and IND-enabling studies by 2026-2027[1][2][3]. Trends like AI-driven antibody design and combo therapies with existing checkpoints will accelerate its pipeline, while expanding autoimmune indications could position it for Big Pharma partnerships. Its influence may grow through milestone payments and potential IPO or acquisition, solidifying European leadership in immune balance restoration—echoing its founding promise of transformative, immunosuppression-free treatments[3][4].
Tridek-One has raised $16.0M in total across 1 funding round.
Tridek-One's investors include Advent Life Sciences, Pureos Bioventures.
Tridek-One has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Venture Round in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $16.0M Venture Round | Advent Life Sciences, Pureos Bioventures |